文献速递临床试验与 GCP新药、器械与细胞基因治疗研发基础与转化研究

瘤内注射溶瘤疱疹病毒G47Δ治疗残留或复发性胶质母细胞瘤:一项2期试验

Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial.
PubMed 文献 · Nat Med · 2022-07-21

这项研究者发起的2期单臂试验评估了三重突变第三代溶瘤单纯疱疹病毒1型G47Δ在19例放疗和替莫唑胺治疗后残留或复发性幕上胶质母细胞瘤成人患者中的疗效。G47Δ瘤内重复给药最多6剂,主要终点G47Δ启动后1年生存率为84.2%(95%CI 60.4-96.6;19例中16例),达到预设终点并提前终止。最常见G47Δ相关不良事件为发热(19例中17例)。

要点

  • G47Δ瘤内重复给药最多6剂,启动后1年生存率84.2%(95%CI 60.4-96.6;16/19),达到预设终点并提前终止。
  • 中位总生存期自G47Δ启动后为20.2(16.8-23.6)个月,自初次手术起为28.8(20.1-37.5)个月。
  • 最常见G47Δ相关不良事件为发热(17/19),其次为呕吐、恶心、淋巴细胞减少和白细胞减少。

核心结论

  • 本研究显示G47Δ具有生存获益和良好安全性特征,并促成G47Δ在日本获批为首个溶瘤病毒产品。

研究设计与样本

  • 研究者发起的2期单臂试验,纳入19例放疗和替莫唑胺治疗后残留或复发性幕上胶质母细胞瘤成人患者(UMIN-CTR临床试验注册号UMIN000015995)。
  • G47Δ为三重突变第三代溶瘤单纯疱疹病毒1型,瘤内重复给药最多6剂。

主要发现

  • 主要终点G47Δ启动后1年生存率为84.2%(95%CI 60.4-96.6;19例中16例),达到预设终点并提前终止试验。
  • 中位总生存期自G47Δ启动后为20.2(16.8-23.6)个月,自初次手术起为28.8(20.1-37.5)个月。
  • 最常见G47Δ相关不良事件为发热(19例中17例),其次为呕吐、恶心、淋巴细胞减少和白细胞减少。
  • 磁共振成像上每次G47Δ给药后靶病灶内反复出现增大及对比增强清除,为该疗法的特征性表现;2年内最佳总体疗效为1例部分缓解、18例疾病稳定。
  • 活检显示肿瘤浸润CD4+/CD8+淋巴细胞数量增加,Foxp3+细胞持续低水平。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This investigator-initiated, phase 2, single-arm trial primarily assessed the efficacy of G47∆, a triple-mutated, third-generation oncolytic herpes simplex virus type 1, in 19 adult patients with residual or recurrent, supratentorial glioblastoma after radiation therapy and temozolomide (UMIN-CTR Clinical Trial Registry UMIN000015995). G47Δ was administered intratumorally and repeatedly for up to six doses. The primary endpoint of 1-yr survival rate after G47∆ initiation was 84.2% (95% confidence interval, 60.4-96.6; 16 of 19). The prespecified endpoint was met and the trial was terminated early. Regarding secondary endpoints, the median overall survival was 20.2 (16.8-23.6) months after G47∆ initiation and 28.8 (20.1-37.5) months from the initial surgery. The most common G47∆-related adverse event was fever (17 of 19) followed by vomiting, nausea, lymphocytopenia and leukopenia. On magnetic resonance imaging, enlargement of and contrast-enhancement clearing within the target lesion repeatedly occurred after each G47∆ administration, which was characteristic to this therapy. Thus, the best overall response in 2 yr was partial response in one patient and stable disease in 18 patients. Biopsies revealed increasing numbers of tumor-infiltrating CD4+/CD8+ lymphocytes and persistent low numbers of Foxp3+ cells. This study showed a survival benefit and good safety profile, which led to the approval of G47∆ as the first oncolytic virus product in Japan.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Todo T, Ito H, Ino Y, et al. Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. Nat Med. 2022. PMID: 35864254. doi:10.1038/s41591-022-01897-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。